🔗 Share this article

While the US proceeds with historic changes to its immunization guidelines, an unexpected name has surfaced in a surprising turn: Tracy Beth Høeg, an American of Danish descent sports physician and public health researcher who rose to prominence by expressing skepticism about Covid shots in the pandemic and has concentrated on alleged fatalities following Covid immunization in her recent tenure at the Food and Drug Administration.

Planned Overhauls to Pediatric Immunization Schedule

Public health authorities were set to reveal radical revisions to the childhood immunization program earlier this month, bringing the US with Denmark’s vaccine program, according to reports – a substantial departure that would place the US out of step with a large portion of the world with little proof for benefit. This reveal has been delayed until the next year.

Instead of Vinay Prasad, Dr. Høeg is listed to present at the meeting. She was newly appointed temporary leader of the FDA’s CDER, the fifth appointee to run the office this year.

Consolidating Power at the Agency

This interim role may indicate a strengthened alliance between the drug and biologics divisions as Dr. Høeg and Prasad strengthen their influence at the FDA – and it signals a renewed priority upon rolling back previously authorized vaccines at the FDA.

The new acting director has repeatedly called for halting some childhood vaccine recommendations in the US to become more similar to Denmark, a country with universal health coverage and a citizenry roughly the population of the state of Wisconsin.

So far comments, she has persisted in emphasizing on vaccination policy – usually the purview of Prasad, chief of the FDA’s CBER – as opposed to drug regulation.

Doubts Over Expertise

Høeg has no obvious experience in pharmaceutical research, regulation or administrative roles, which has been typical for former directors of the biologics center. She has been employed at the FDA as a top consultant to the commissioner and the vaccine center since earlier this year.

“She appears not to have any of the qualifications” for leading the drug-regulation department, said Jonathan Howard. “She has not conducted a scientific study. She is not versed in managing a major agency. She is not an expert in industry regulation.”

Former directors of CBER would “understand legal statutes and the research of drug development”, noted Dr. Janet Woodcock. “Clearly, she lacks the sort of resume that previous people who led CBER have had.”

CDER has an enormous range of responsibilities at the agency, Woodcock pointed out.

“The public just focuses on the innovative therapies, but the generic program approves a multitude of off-brand pharmaceuticals. There’s a biosimilars division, over-the-counter program and other areas, and each of these have to be looked after,” she noted. “The area you don’t keep your eye on, that is the part that I always told people is going to come back to haunt you.”

There is also, a substantial management aspect to the job, which manages over 5,000 personnel. “It’s a massive leadership role, if you do it right,” Woodcock concluded.

Agency Reaction and Disputed Initiatives

When asked about concerns about Dr. Høeg's credentials and whether this selection represents increased cooperation among FDA leaders on vaccines, a representative said that the “questions are based on inaccurate presumptions”.

“Her resume aligns with the functions of her role,” the official said, pointing to the time Dr. Høeg spent advising the FDA commissioner on “medication safety and oversight research, including computational safety modeling and immunization monitoring”.

In her interim role, Høeg takes over the commissioner’s recently launched fast-track approval initiative, a disputed one-day drug-approval program that apparently troubled her preceding directors. “How are these drugs being picked for this voucher program? Who is making the calls?” Dr. Howard said. “There is a lot of confidentiality occurring at the FDA right now.”

Broadly speaking, he remarked, “the Food and Drug Administration appears to be shifting towards less stringent regulations of most medications, with the exception of shots.”

Public History on Vaccines

Concerning immunizations, Høeg has a clearer, if problematic, track record, some experts said. She authored a study using unconfirmed volunteer-provided data to estimate the frequency of myocarditis after Covid vaccination. She consulted for the state of Florida top health official Dr. Joseph Ladapo, who was said to have altered data to imply Covid vaccinations are riskier than they are.

Included in her “wish list” for the new government included changing guidelines for novel immunizations and ending “optional” immunizations, she stated following the vote on a online show. At the FDA, Dr. Høeg has according to sources suggested preventing young men from obtaining COVID-19 vaccinations.

“She is an all-around dogmatist who begins with her conclusions and tailors the evidence to retrofit the evidence in a very misleading, untruthful manner,” Howard stated.

Consolidating Power and a “Push for Payback”

Høeg aligned with other skeptics, {like|